1. Search Result
Search Result
Results for "

influenza virus

" in MedChemExpress (MCE) Product Catalog:

299

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

27

Peptides

6

Inhibitory Antibodies

56

Natural
Products

6

Recombinant Proteins

23

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155476

    Influenza Virus Infection
    Influenza virus-IN-8 (compound A4) is an inhibitor of influenza virus (Influenza Virus) that induces viral nucleoprotein (NP) aggregation and prevents its nuclear accumulation. Influenza virus-IN-8 has broad-spectrum anti-influenza activity and can inhibit the replication and transcription of influenza A virus. Influenza virus-IN-8 also inhibits Oseltamivir (HY-13317)-resistant H1N1/pdm09 strains .
    Influenza virus-IN-8
  • HY-146147

    Influenza Virus Infection
    Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against influenza A/H3N2 virus .
    Influenza virus-IN-5
  • HY-143492

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-1 (compound 14) is a potent influenza A virus inhibitor with an EC50 of 2.46 µM and CC50 of >200 µM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 312.36 nM. Influenza virus-IN-1 shows shows anti-influenza A virus activities .
    Influenza virus-IN-1
  • HY-143493

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-2 (compound 19) is a potent influenza virus inhibitor with an EC50 of 2.58 µM and CC50 of 150.85 µM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 489.39 nM. Influenza virus-IN-2 shows shows anti-influenza A virus activities .
    Influenza virus-IN-2
  • HY-146001

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-4 (compound 11e) is a potent influenza virus neuraminidase inhibitor with IC50s of 3.4, 0.094, 0.79, 0.077 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-4 shows low cytotoxicity with an CC50 of >200 µM. Influenza virus-IN-4 shows no obvious toxicity at the dose of 1500 mg/kg in mice .
    Influenza virus-IN-4
  • HY-146000

    Influenza Virus Inflammation/Immunology
    Influenza virus-IN-3 (compound 9) is a potent and selective influenza virus inhibitor with IC50s of 0.88, 0.10, 5.5, 0.51 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-3 shows antiviral and NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-3 shows low cytotoxicity with an CC50 of >200 µM .
    Influenza virus-IN-3
  • HY-153570

    Influenza Virus Infection
    Influenza virus-IN-7 (Example 16) is an orally active cap-dependent endonuclease inhibitor that can be used for the research of influenza viral infectious diseases .
    Influenza virus-IN-7
  • HY-152078

    Influenza Virus Infection
    Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PAN) endonuclease inhibitor with an IC50 of 0.20 μM .
    Influenza virus-IN-6
  • HY-146004

    Influenza Virus Infection
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses .
    Influenza A virus-IN-4
  • HY-149034

    S5

    Influenza Virus Infection
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
    Influenza A virus-IN-8
  • HY-162492

    Influenza Virus Infection
    Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
    Influenza A virus-IN-14
  • HY-P1857

    Influenza Virus Infection
    CEF7, Influenza Virus NP (380-388) is a HLA-B *08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .
    CEF7, Influenza Virus NP (380-388)
  • HY-131179

    Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-P1835

    Influenza Virus Inflammation/Immunology
    CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B *2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .
    CEF8, Influenza Virus NP (383-391)
  • HY-112543

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV) .
    S119-8
  • HY-156288

    Influenza Virus Infection
    Anti-Influenza agent 5 (Compound IIB-2), chalcone-like derivative, is an influenza nuclear export inhibitor. Anti-Influenza agent 5 has inhibitory effects on oseltamivir-resistant strains. Anti-Influenza agent 5 can impede virus proliferation by blocking the export of influenza virus nucleoprotein .
    Anti-Influenza agent 5
  • HY-131069A

    Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .
    MBX2329
  • HY-152239

    Influenza Virus Infection
    RdRP-IN-5 (compound 20) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. RdRP-IN-5 can be used in research of influenza virus .
    RdRP-IN-5
  • HY-152239A

    Influenza Virus Infection
    cis-RdRP-IN-5 (compound 19) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. cis-RdRP-IN-5 can be used in research of influenza virus .
    cis-RdRP-IN-5
  • HY-152239B

    Influenza Virus Infection
    trans-RdRP-IN-5 (compound 18) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. trans-RdRP-IN-5 can be used in research of influenza virus .
    trans-RdRP-IN-5
  • HY-119213

    Influenza Virus Infection
    BMY-27709 is an influenza virus growth inhibitor with an IC50 value of 3-8 μM against A/WSN/33 virus growth, and also exhibits inhibitory activity against some subtypes of influenza viruses. BMY-27709 acts early in the course of H1 and H2 virus infections, and exhibits antiviral activity through inhibition of hemagglutinin proteins. However, BMY-27709 has no effect on H3 subtype viruses and influenza B/Lee/40 viruses .
    BMY-27709
  • HY-144066

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
    Cap-dependent endonuclease-IN-21
  • HY-144067

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
    Cap-dependent endonuclease-IN-23
  • HY-123304

    Influenza Virus Infection
    MBX2546 is a influenza A virus inhibitor with the Kd values of 5.3μM and > 100 μM for H1 Hemagglutinin and H3 Hemagglutinin, respectively .
    MBX2546
  • HY-122261

    DU-34569 maleate

    Others Infection
    Spiroamantadine (DU-34569 maleate) is a compound related to Amantadine (HY-B0402) with anti-influenza virus activity .
    Spiroamantadine
  • HY-116182

    Influenza Virus Infection
    RO5487624, an analogue of RO5464466 (HY-120690), is an orally active hemagglutinin (HA) inhibitor of influenza H1N1 viruses that abolishes influenza virus fusion by blocking HA conformational changes in low pH environments. RO5487624 displays a protective effect on mice that are lethally challenged with influenza H1N1 virus .
    RO5487624
  • HY-P5643

    Bacterial Infection
    Retrocyclin-2 is an antimicrobial peptide against human immunodeficiency virus, influenza A and herpes simplex virus .
    Retrocyclin-2
  • HY-P5644

    Bacterial Infection
    Retrocyclin-3 is an antimicrobial peptide against human immunodeficiency virus, influenza A and herpes simplex virus .
    Retrocyclin-3
  • HY-P99750

    CT-P23

    Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-155110

    Influenza Virus Infection
    Antiviral agent 34 is a potent and orally active antiviral agent against influenza A and B subtypes with an EC50 value of 0.8 nM for H1N1 proliferation. Antiviral agent 34 derivatives inhibited influenza virus proliferation by targeting influenza virus RNA-dependent RNA polymerase. Antiviral agent 34 can be used for influenza virus research .
    Antiviral agent 34
  • HY-W012738

    Influenza Virus GABA Receptor Infection
    DL-Pyroglutamic acid (CAE) as an inactivator of hepatitis B surface, inactivates vaccinia virus, herpes simplex virus, and influenza virus except poliovirus. DL-Pyroglutamic acid is also a possible inhibitor of GABA transaminase, increases GABA amount with antiepileptic action .
    DL-Pyroglutamic acid
  • HY-143495

    RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
    RSV-IN-3
  • HY-143496

    RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
    RSV-IN-4
  • HY-N10581

    Influenza Virus Infection
    Flutimide is a novel endonuclease inhibitor of influenza virus. Flutimide selectively inhibits endonuclease with an IC50 value of 3 μM. Flutimide shows antiviral activity in cell culture. Flutimide can be used for the research of acute contagious respiratory disease, such as influenza .
    Flutimide
  • HY-143766

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .
    Cap-dependent endonuclease-IN-13
  • HY-P2561

    Influenza Virus Infection Inflammation/Immunology
    Influenza Matrix Protein (61-72) is a peptide fragment derived from matrix protein of influenza viruses, corresponds to amino acids 61-72. Influenza Matrix Protein (61-72) is a specific epitope which can induce CD4 + T-cell response .
    Influenza Matrix Protein (61-72)
  • HY-N12362

    Influenza Virus Infection
    Antiviral agent 41 (compound 5) is a diarylheptanoid isolated from Alpinia officinarum. Antiviral agent 41 exhibits potential antiviral activity against influenza virus in vitro .
    Antiviral agent 41
  • HY-137660

    Others Infection
    pppApG is a starting product of both vRNA (viral RNA) and cRNA (complementary RNA) synthesis. pppApG can be used for influenza virus research .
    pppApG
  • HY-137334

    Influenza Virus Infection
    Neuraminidase-IN-1 is a neuraminidase inhibitor, with an IC50 of 0.21 μM. Neuraminidase-IN-1 has excellent activity against H1N1 influenza virus .
    Neuraminidase-IN-1
  • HY-164390

    Neu5Acα2-6Galβ1-4GlcNAc

    Endogenous Metabolite Infection Cancer
    6′SLN is a cancer-related extracellular vesicle (EVs) surface glycan that serves as a key form of protein glycosylation in EVs. 6′SLN is also a sialic acid derivative that can interact with hemagglutinins (HAs) from human and avian influenza virus strains, making it useful for research into anti-influenza drugs .
    6′SLN
  • HY-105395

    Influenza Virus Infection
    BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC50s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model .
    BCX-1898
  • HY-143744

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
    Cap-dependent endonuclease-IN-3
  • HY-145391

    Influenza Virus Infection
    Triperiden is an inhibitor of influenza virus multiplication. Triperiden targets the haemagglutinin of fowl plague virus (FPV) for antiviral activity and acts by inhibiting the conformational change in the haemagglutinin at acid pH. Triperiden is also anticholinergic anti-parkinsonism agent .
    Triperiden
  • HY-139558

    PD0184264; ATR-002

    MEK Influenza Virus Bacterial Infection Cancer
    Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities .
    Zapnometinib
  • HY-156048

    TFMT

    Influenza Virus Infection
    Trifluoromethyl-tubercidin (TFMT) is a 2'-O-ribose methyltransferase 1 (MTr1) inhibitor through interaction at its S-adenosyl-l-methionine binding pocket to restrict influenza virus replication .
    Trifluoromethyl-tubercidin
  • HY-125540

    Influenza Virus Infection Inflammation/Immunology
    Saussureamine C shows gastroprotective effect on acidified ethanol-induced gastric mucosal lesions in rats. Saussureamine C inhibits H274Y and N294S mutants and can be used for research of influenza virus infection. Saussureamine C can be isolated from the dried roots of Saussurea lappa Clarke .
    Saussureamine C
  • HY-143768

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .
    Cap-dependent endonuclease-IN-14
  • HY-143769

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .
    Cap-dependent endonuclease-IN-15
  • HY-163659

    Influenza Virus Infection
    Anti-Influenza agent 6 (compound 19b) shows inhibitory activity against A/WSN/33/H1N1 (EC50 = 0.015 μM) and influenza B virus Yamagata/16/88 (EC50 = 0.073 μM) and Victotis/2/87 (EC50 = 0.067 μM) .
    Anti-Influenza agent 6
  • HY-W011518

    Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation .
    2′-Deoxy-2′-fluoroguanosine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: